Aktis Oncology
AKTS
69 hedge funds and large institutions have $630M invested in Aktis Oncology in 2026 Q1 according to their latest regulatory filings, with 69 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
75.42% more ownership
Funds ownership: 0% → 75.42% (+75%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$93.9M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$93.7M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
+$61.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$45M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$41.2M |
Top Sellers
AKTS Hedge Fund Activity: Q1 2026 in Review
69 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Aktis Oncology (AKTS) for Q1 2026, worth a combined $630M.
Buyers outnumbered sellers: 69 funds opened new AKTS positions and 0 closed out — a net gain of 69 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $93.9M.
- 69 institutional investors held Aktis Oncology (AKTS) as of Q1 2026, up from 0 in Q4 2025.
- Funds reported $630M of Aktis Oncology stock for Q1 2026.
- 69 funds opened new Aktis Oncology positions in Q1 2026 and 0 closed out, a net change of +69 holders.
- The largest Aktis Oncology buyer in Q1 2026 was MPM BioImpact, an estimated $93.9M added.
Based on aggregated 13F filings for Q1 2026.